RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: microcirculation using the video microscopy tool. for Cardiogenic Shock

Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.

Official registry: https://clinicaltrials.gov/study/NCT07141355 · University Hospital, Strasbourg, France · enrollment listed as 24

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are microcirculation using the video microscopy tool.. The registry lists allocation as randomized. Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%.

They plan to enroll about 24 people at Strasbourg. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Microcirculatory Effects of Empagliflozin in Patients With Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

Interventions: microcirculation using the video microscopy tool.

Primary outcome (registry wording): The difference in the evolution of a parameter reflecting the microcirculation between the two groups at 48 hours post-randomization.

Who it is for (from inclusion criteria)

Ages 18 Years to any
Patient included in the main EMPASHOCK study
Patient has signed a consent form for the ancillary study
Patient is over 18 years old
Hospitalized in the Intensive Care Unit for cardiogenic shock\*
Has been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock\*\*
Patient has the ability to take tablets orally
Person is affiliated with or a beneficiary of a social security system

Who the registry excludes

GFR \< 20 ml/min/1.73m²
Patient on SGLT2 inhibitors prior to ICU admission
Known allergy to SGLT2 inhibitors or any of their excipients (in particular, patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome)
Patient with type 1 diabetes
Patient in shock due to another cause or moribund patient (IGS 2 \> 90)
Woman of childbearing age without effective contraception
Person referred to in Articles 10, 31, 32, 33, and 34 of EU Regulation 536/2014, specifically:

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

Hôpitaux Universitaires de Strasbourg — Strasbourg, France (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07141355 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07141355?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07141355?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary